The global New Drug for Alzheimer's Treatment market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.

From a downstream perspective, Preclinical Stage accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).

New Drug for Alzheimer's Treatment leading manufacturers including Biogen, Eisai, Eli Lilly, Neurimmune, Roche, AstraZeneca, Green Valley, Vivoryon, Simcere, Johnson and Johnson, etc., dominate supply; the top five capture approximately % of global revenue, with Biogen leading 2024 sales at US$ million.

Regional Outlook:

North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).

Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).

Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global New Drug for Alzheimer's Treatment market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.

By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.

Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.

Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.

Market Segmentation

Scope of New Drug for Alzheimer's Treatment Market Report

Report Metric	Details
Report Name	New Drug for Alzheimer's Treatment Market
Segment by Type	AChE Target Aβ Target BChE Target Others
Segment by Application	Preclinical Stage Mild Cognitive Impairment Stage Dementia Stage
Sales by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Biogen, Eisai, Eli Lilly, Neurimmune, Roche, AstraZeneca, Green Valley, Vivoryon, Simcere, Johnson and Johnson
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the New Drug for Alzheimer's Treatment study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the New Drug for Alzheimer's Treatment Market report?

Ans: The main players in the New Drug for Alzheimer's Treatment Market are Biogen, Eisai, Eli Lilly, Neurimmune, Roche, AstraZeneca, Green Valley, Vivoryon, Simcere, Johnson and Johnson

What are the Application segmentation covered in the New Drug for Alzheimer's Treatment Market report?

Ans: The Applications covered in the New Drug for Alzheimer's Treatment Market report are Preclinical Stage, Mild Cognitive Impairment Stage, Dementia Stage

What are the Type segmentation covered in the New Drug for Alzheimer's Treatment Market report?

Ans: The Types covered in the New Drug for Alzheimer's Treatment Market report are AChE Target, Aβ Target, BChE Target, Others

1 Study Coverage

1.1 Introduction to New Drug for Alzheimer's Treatment: Definition, Properties, and Key Attributes

1.2 Market Segmentation by Type

1.2.1 Global New Drug for Alzheimer's Treatment Market Size by Type, 2020 VS 2024 VS 2031

1.2.2 AChE Target

1.2.3 Aβ Target

1.2.4 BChE Target

1.2.5 Others

1.3 Market Segmentation by Application

1.3.1 Global New Drug for Alzheimer's Treatment Market Size by Application, 2020 VS 2024 VS 2031

1.3.2 Preclinical Stage

1.3.3 Mild Cognitive Impairment Stage

1.3.4 Dementia Stage

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Executive Summary

2.1 Global New Drug for Alzheimer's Treatment Revenue Estimates and Forecasts 2020-2031

2.2 Global New Drug for Alzheimer's Treatment Revenue by Region

2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031

2.2.2 Historical and Forecasted Revenue by Region (2020--2031)

2.2.3 Global Revenue Market Share by Region (2020-2031)

2.3 Global New Drug for Alzheimer's Treatment Sales Estimates and Forecasts 2020-2031

2.4 Global New Drug for Alzheimer's Treatment Sales by Region

2.4.1 Sales Comparison: 2020 VS 2024 VS 2031

2.4.2 Historical and Forecasted Sales by Region (2020-2031)

2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends

2.4.4 Global Sales Market Share by Region (2020-2031)

3 Competition by Manufacturers

3.1 Global New Drug for Alzheimer's Treatment Sales by Manufacturers

3.1.1 Global Sales Volume by Manufacturers (2020-2025)

3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)

3.2 Global New Drug for Alzheimer's Treatment Manufacturer Revenue Rankings and Tiers

3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)

3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)

3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)

3.3 Manufacturer Profitability Profiles and Pricing Strategies

3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)

3.3.2 Manufacturer-Level Price Trends (2020-2025)

3.4 Key Manufacturers Manufacturing Base and Headquarters

3.5 Main Product Type Market Size by Manufacturers

3.5.1 AChE Target Market Size by Manufacturers

3.5.2 Aβ Target Market Size by Manufacturers

3.5.3 BChE Target Market Size by Manufacturers

3.5.4 Others Market Size by Manufacturers

3.6 Global New Drug for Alzheimer's Treatment Market Concentration and Dynamics

3.6.1 Global Market Concentration (CR5 and HHI)

3.6.2 Entrant/Exit Impact Analysis

3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment

4 Global Product Segmentation Analysis

4.1 Global New Drug for Alzheimer's Treatment Sales Performance by Type

4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)

4.1.2 Global Sales Market Share by Type (2020-2031)

4.2 Global New Drug for Alzheimer's Treatment Revenue Trends by Type

4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)

4.2.2 Global Revenue Market Share by Type (2020-2031)

4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)

4.4 Product Technology Differentiation

4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk

4.5.1 High-Growth Niches and Adoption Drivers

4.5.2 Profitability Hotspots and Cost Drivers

4.5.3 Substitution Threats

5 Global Downstream Application Analysis

5.1 Global New Drug for Alzheimer's Treatment Sales by Application

5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)

5.1.2 Global Sales Market Share by Application (2020-2031)

5.1.3 High-Growth Application Identification

5.1.4 Emerging Application Case Studies

5.2 Global New Drug for Alzheimer's Treatment Revenue by Application

5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)

5.2.2 Revenue Market Share by Application (2020-2031)

5.3 Global Pricing Dynamics by Application (2020-2031)

5.4 Downstream Customer Analysis

5.4.1 Top Customers by Region

5.4.2 Top Customers by Application

6 North America

6.1 North America Sales Volume and Revenue (2020-2031)

6.2 North America Key Manufacturers Sales Revenue in 2024

6.3 North America New Drug for Alzheimer's Treatment Sales and Revenue by Type (2020-2031)

6.4 North America New Drug for Alzheimer's Treatment Sales and Revenue by Application (2020-2031)

6.5 North America Growth Accelerators and Market Barriers

6.6 North America New Drug for Alzheimer's Treatment Market Size by Country

6.6.1 North America Revenue by Country

6.6.2 North America Sales Trends by Country

6.6.3 US

6.6.4 Canada

6.6.5 Mexico

7 Europe

7.1 Europe Sales Volume and Revenue (2020-2031)

7.2 Europe Key Manufacturers Sales Revenue in 2024

7.3 Europe New Drug for Alzheimer's Treatment Sales and Revenue by Type (2020-2031)

7.4 Europe New Drug for Alzheimer's Treatment Sales and Revenue by Application (2020-2031)

7.5 Europe Growth Accelerators and Market Barriers

7.6 Europe New Drug for Alzheimer's Treatment Market Size by Country

7.6.1 Europe Revenue by Country

7.6.2 Europe Sales Trends by Country

7.6.3 Germany

7.6.4 France

7.6.5 U.K.

7.6.6 Italy

7.6.7 Russia

8 Asia-Pacific

8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)

8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024

8.3 Asia-Pacific New Drug for Alzheimer's Treatment Sales and Revenue by Type (2020-2031)

8.4 Asia-Pacific New Drug for Alzheimer's Treatment Sales and Revenue by Application (2020-2031)

8.5 Asia-Pacific New Drug for Alzheimer's Treatment Market Size by Region

8.5.1 Asia-Pacific Revenue by Region

8.5.2 Asia-Pacific Sales Trends by Region

8.6 Asia-Pacific Growth Accelerators and Market Barriers

8.7 Southeast Asia

8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)

8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines

8.8 China

8.9 Japan

8.10 South Korea

8.11 China Taiwan

8.12 India

9 Central and South America

9.1 Central and South America Sales Volume and Revenue (2020-2031)

9.2 Central and South America Key Manufacturers Sales Revenue in 2024

9.3 Central and South America New Drug for Alzheimer's Treatment Sales and Revenue by Type (2020-2031)

9.4 Central and South America New Drug for Alzheimer's Treatment Sales and Revenue by Application (2020-2031)

9.5 Central and South America Investment Opportunities and Key Challenges

9.6 Central and South America New Drug for Alzheimer's Treatment Market Size by Country

9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)

9.6.2 Brazil

9.6.3 Argentina

10 Middle East and Africa

10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)

10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024

10.3 Middle East and Africa New Drug for Alzheimer's Treatment Sales and Revenue by Type (2020-2031)

10.4 Middle East and Africa New Drug for Alzheimer's Treatment Sales and Revenue by Application (2020-2031)

10.5 Middle East and Africa Investment Opportunities and Key Challenges

10.6 Middle East and Africa New Drug for Alzheimer's Treatment Market Size by Country

10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)

10.6.2 GCC Countries

10.6.3 Turkey

10.6.4 Egypt

10.6.5 South Africa

11 Corporate Profile

11.1 Biogen

11.1.1 Biogen Corporation Information

11.1.2 Biogen Business Overview

11.1.3 Biogen New Drug for Alzheimer's Treatment Product Models, Descriptions and Specifications

11.1.4 Biogen New Drug for Alzheimer's Treatment Sales, Price, Revenue and Gross Margin (2020-2025)

11.1.5 Biogen New Drug for Alzheimer's Treatment Sales by Product in 2024

11.1.6 Biogen New Drug for Alzheimer's Treatment Sales by Application in 2024

11.1.7 Biogen New Drug for Alzheimer's Treatment Sales by Geographic Area in 2024

11.1.8 Biogen New Drug for Alzheimer's Treatment SWOT Analysis

11.1.9 Biogen Recent Developments

11.2 Eisai

11.2.1 Eisai Corporation Information

11.2.2 Eisai Business Overview

11.2.3 Eisai New Drug for Alzheimer's Treatment Product Models, Descriptions and Specifications

11.2.4 Eisai New Drug for Alzheimer's Treatment Sales, Price, Revenue and Gross Margin (2020-2025)

11.2.5 Eisai New Drug for Alzheimer's Treatment Sales by Product in 2024

11.2.6 Eisai New Drug for Alzheimer's Treatment Sales by Application in 2024

11.2.7 Eisai New Drug for Alzheimer's Treatment Sales by Geographic Area in 2024

11.2.8 Eisai New Drug for Alzheimer's Treatment SWOT Analysis

11.2.9 Eisai Recent Developments

11.3 Eli Lilly

11.3.1 Eli Lilly Corporation Information

11.3.2 Eli Lilly Business Overview

11.3.3 Eli Lilly New Drug for Alzheimer's Treatment Product Models, Descriptions and Specifications

11.3.4 Eli Lilly New Drug for Alzheimer's Treatment Sales, Price, Revenue and Gross Margin (2020-2025)

11.3.5 Eli Lilly New Drug for Alzheimer's Treatment Sales by Product in 2024

11.3.6 Eli Lilly New Drug for Alzheimer's Treatment Sales by Application in 2024

11.3.7 Eli Lilly New Drug for Alzheimer's Treatment Sales by Geographic Area in 2024

11.3.8 Eli Lilly New Drug for Alzheimer's Treatment SWOT Analysis

11.3.9 Eli Lilly Recent Developments

11.4 Neurimmune

11.4.1 Neurimmune Corporation Information

11.4.2 Neurimmune Business Overview

11.4.3 Neurimmune New Drug for Alzheimer's Treatment Product Models, Descriptions and Specifications

11.4.4 Neurimmune New Drug for Alzheimer's Treatment Sales, Price, Revenue and Gross Margin (2020-2025)

11.4.5 Neurimmune New Drug for Alzheimer's Treatment Sales by Product in 2024

11.4.6 Neurimmune New Drug for Alzheimer's Treatment Sales by Application in 2024

11.4.7 Neurimmune New Drug for Alzheimer's Treatment Sales by Geographic Area in 2024

11.4.8 Neurimmune New Drug for Alzheimer's Treatment SWOT Analysis

11.4.9 Neurimmune Recent Developments

11.5 Roche

11.5.1 Roche Corporation Information

11.5.2 Roche Business Overview

11.5.3 Roche New Drug for Alzheimer's Treatment Product Models, Descriptions and Specifications

11.5.4 Roche New Drug for Alzheimer's Treatment Sales, Price, Revenue and Gross Margin (2020-2025)

11.5.5 Roche New Drug for Alzheimer's Treatment Sales by Product in 2024

11.5.6 Roche New Drug for Alzheimer's Treatment Sales by Application in 2024

11.5.7 Roche New Drug for Alzheimer's Treatment Sales by Geographic Area in 2024

11.5.8 Roche New Drug for Alzheimer's Treatment SWOT Analysis

11.5.9 Roche Recent Developments

11.6 AstraZeneca

11.6.1 AstraZeneca Corporation Information

11.6.2 AstraZeneca Business Overview

11.6.3 AstraZeneca New Drug for Alzheimer's Treatment Product Models, Descriptions and Specifications

11.6.4 AstraZeneca New Drug for Alzheimer's Treatment Sales, Price, Revenue and Gross Margin (2020-2025)

11.6.5 AstraZeneca Recent Developments

11.7 Green Valley

11.7.1 Green Valley Corporation Information

11.7.2 Green Valley Business Overview

11.7.3 Green Valley New Drug for Alzheimer's Treatment Product Models, Descriptions and Specifications

11.7.4 Green Valley New Drug for Alzheimer's Treatment Sales, Price, Revenue and Gross Margin (2020-2025)

11.7.5 Green Valley Recent Developments

11.8 Vivoryon

11.8.1 Vivoryon Corporation Information

11.8.2 Vivoryon Business Overview

11.8.3 Vivoryon New Drug for Alzheimer's Treatment Product Models, Descriptions and Specifications

11.8.4 Vivoryon New Drug for Alzheimer's Treatment Sales, Price, Revenue and Gross Margin (2020-2025)

11.8.5 Vivoryon Recent Developments

11.9 Simcere

11.9.1 Simcere Corporation Information

11.9.2 Simcere Business Overview

11.9.3 Simcere New Drug for Alzheimer's Treatment Product Models, Descriptions and Specifications

11.9.4 Simcere New Drug for Alzheimer's Treatment Sales, Price, Revenue and Gross Margin (2020-2025)

11.9.5 Simcere Recent Developments

11.10 Johnson and Johnson

11.10.1 Johnson and Johnson Corporation Information

11.10.2 Johnson and Johnson Business Overview

11.10.3 Johnson and Johnson New Drug for Alzheimer's Treatment Product Models, Descriptions and Specifications

11.10.4 Johnson and Johnson New Drug for Alzheimer's Treatment Sales, Price, Revenue and Gross Margin (2020-2025)

11.10.5 Johnson and Johnson Recent Developments

12 Value Chain and Supply-Chain Analysis

12.1 New Drug for Alzheimer's Treatment Industry Chain

12.2 New Drug for Alzheimer's Treatment Upstream Materials Analysis

12.2.1 Raw Materials

12.2.2 Key Suppliers Market Share & Risk Assessment

12.3 New Drug for Alzheimer's Treatment Integrated Production Analysis

12.3.1 Manufacturing Footprint Analysis

12.3.2 Regional Production Market Share (2020-2031)

12.3.3 Regulatory and Trade Policy Impact on Production

12.3.4 Production Technology Overview

12.3.5 Regional Cost Drivers

12.4 New Drug for Alzheimer's Treatment Sales Channels and Distribution Networks

12.4.1 Sales Channels

12.4.2 Distributors

13 New Drug for Alzheimer's Treatment Market Dynamics

13.1 Industry Trends and Evolution

13.2 Market Growth Drivers and Emerging Opportunities

13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global New Drug for Alzheimer's Treatment Study

15 Appendix

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.1.1 Research Programs/Design

15.1.1.2 Market Size Estimation

15.1.1.3 Market Breakdown and Data Triangulation

15.1.2 Data Source

15.1.2.1 Secondary Sources

15.1.2.2 Primary Sources

15.2 Author Details

FEATURED COMPANIES

List of Tables

Table 1. Global New Drug for Alzheimer's Treatment Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Table 2. Global New Drug for Alzheimer's Treatment Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Table 3. Global New Drug for Alzheimer's Treatment Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 4. Global New Drug for Alzheimer's Treatment Revenue by Region (2020-2025) & (US$ Million)

Table 5. Global New Drug for Alzheimer's Treatment Revenue by Region (2026-2031) & (US$ Million)

Table 6. Global New Drug for Alzheimer's Treatment Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Dose)

Table 7. Global New Drug for Alzheimer's Treatment Sales by Region (2020-2025) & (K Dose)

Table 8. Global New Drug for Alzheimer's Treatment Sales by Region (2026-2031) & (K Dose)

Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 10. Global New Drug for Alzheimer's Treatment Sales by Manufacturers (2020-2025) & (K Dose)

Table 11. Global New Drug for Alzheimer's Treatment Sales Share by Manufacturers (2020-2025)

Table 12. Global New Drug for Alzheimer's Treatment Revenue by Manufacturers (2020-2025) & (US$ Million)

Table 13. Global New Drug for Alzheimer's Treatment Revenue Market Share by Manufacturers (2020-2025)

Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)

Table 15. Global New Drug for Alzheimer's Treatment by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in New Drug for Alzheimer's Treatment as of 2024)

Table 16. Global New Drug for Alzheimer's Treatment Average Gross Margin (%) by Manufacturer (2020 VS 2024)

Table 17. Global New Drug for Alzheimer's Treatment Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Dose)

Table 18. Key Manufacturers New Drug for Alzheimer's Treatment Manufacturing Base and Headquarters

Table 19. Global New Drug for Alzheimer's Treatment Market Concentration Ratio (CR5 and HHI)

Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis

Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment

Table 22. Global New Drug for Alzheimer's Treatment Sales by Type (2020-2025) & (K Dose)

Table 23. Global New Drug for Alzheimer's Treatment Sales by Type (2026-2031) & (K Dose)

Table 24. Global New Drug for Alzheimer's Treatment Revenue by Type (2020-2025) & (US$ Million)

Table 25. Global New Drug for Alzheimer's Treatment Revenue by Type (2026-2031) & (US$ Million)

Table 26. Global New Drug for Alzheimer's Treatment ASP by Type (2020-2031) & (US$/Dose)

Table 27. Technical Specifications by Key Product Type

Table 28. Global New Drug for Alzheimer's Treatment Sales by Application (2020-2025) & (K Dose)

Table 29. Global New Drug for Alzheimer's Treatment Sales by Application (2026-2031) & (K Dose)

Table 30. New Drug for Alzheimer's Treatment High-Growth Sectors Demand CAGR (2024-2031)

Table 31. Global New Drug for Alzheimer's Treatment Revenue by Application (2020-2025) & (US$ Million)

Table 32. Global New Drug for Alzheimer's Treatment Revenue by Application (2026-2031) & (US$ Million)

Table 33. Global New Drug for Alzheimer's Treatment ASP by Application (2020-2031) & (US$/Dose)

Table 34. Top Customers by Region

Table 35. Top Customers by Application

Table 36. North America New Drug for Alzheimer's Treatment Growth Accelerators and Market Barriers

Table 37. North America New Drug for Alzheimer's Treatment Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 38. North America New Drug for Alzheimer's Treatment Sales (K Dose) by Country (2020 VS 2024 VS 2031)

Table 39. Europe New Drug for Alzheimer's Treatment Growth Accelerators and Market Barriers

Table 40. Europe New Drug for Alzheimer's Treatment Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Europe New Drug for Alzheimer's Treatment Sales (K Dose) by Country (2020 VS 2024 VS 2031)

Table 42. Asia-Pacific New Drug for Alzheimer's Treatment Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 43. Asia-Pacific New Drug for Alzheimer's Treatment Sales (K Dose) by Country (2020 VS 2024 VS 2031)

Table 44. Asia-Pacific New Drug for Alzheimer's Treatment Growth Accelerators and Market Barriers

Table 45. Southeast Asia New Drug for Alzheimer's Treatment Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Central and South America New Drug for Alzheimer's Treatment Investment Opportunities and Key Challenges

Table 47. Central and South America New Drug for Alzheimer's Treatment Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 48. Middle East and Africa New Drug for Alzheimer's Treatment Investment Opportunities and Key Challenges

Table 49. Middle East and Africa New Drug for Alzheimer's Treatment Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 50. Biogen Corporation Information

Table 51. Biogen Description and Major Businesses

Table 52. Biogen Product Models, Descriptions and Specifications

Table 53. Biogen Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 54. Biogen Sales Value Proportion by Product in 2024

Table 55. Biogen Sales Value Proportion by Application in 2024

Table 56. Biogen Sales Value Proportion by Geographic Area in 2024

Table 57. Biogen New Drug for Alzheimer's Treatment SWOT Analysis

Table 58. Biogen Recent Developments

Table 59. Eisai Corporation Information

Table 60. Eisai Description and Major Businesses

Table 61. Eisai Product Models, Descriptions and Specifications

Table 62. Eisai Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 63. Eisai Sales Value Proportion by Product in 2024

Table 64. Eisai Sales Value Proportion by Application in 2024

Table 65. Eisai Sales Value Proportion by Geographic Area in 2024

Table 66. Eisai New Drug for Alzheimer's Treatment SWOT Analysis

Table 67. Eisai Recent Developments

Table 68. Eli Lilly Corporation Information

Table 69. Eli Lilly Description and Major Businesses

Table 70. Eli Lilly Product Models, Descriptions and Specifications

Table 71. Eli Lilly Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 72. Eli Lilly Sales Value Proportion by Product in 2024

Table 73. Eli Lilly Sales Value Proportion by Application in 2024

Table 74. Eli Lilly Sales Value Proportion by Geographic Area in 2024

Table 75. Eli Lilly New Drug for Alzheimer's Treatment SWOT Analysis

Table 76. Eli Lilly Recent Developments

Table 77. Neurimmune Corporation Information

Table 78. Neurimmune Description and Major Businesses

Table 79. Neurimmune Product Models, Descriptions and Specifications

Table 80. Neurimmune Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 81. Neurimmune Sales Value Proportion by Product in 2024

Table 82. Neurimmune Sales Value Proportion by Application in 2024

Table 83. Neurimmune Sales Value Proportion by Geographic Area in 2024

Table 84. Neurimmune New Drug for Alzheimer's Treatment SWOT Analysis

Table 85. Neurimmune Recent Developments

Table 86. Roche Corporation Information

Table 87. Roche Description and Major Businesses

Table 88. Roche Product Models, Descriptions and Specifications

Table 89. Roche Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 90. Roche Sales Value Proportion by Product in 2024

Table 91. Roche Sales Value Proportion by Application in 2024

Table 92. Roche Sales Value Proportion by Geographic Area in 2024

Table 93. Roche New Drug for Alzheimer's Treatment SWOT Analysis

Table 94. Roche Recent Developments

Table 95. AstraZeneca Corporation Information

Table 96. AstraZeneca Description and Major Businesses

Table 97. AstraZeneca Product Models, Descriptions and Specifications

Table 98. AstraZeneca Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 99. AstraZeneca Recent Developments

Table 100. Green Valley Corporation Information

Table 101. Green Valley Description and Major Businesses

Table 102. Green Valley Product Models, Descriptions and Specifications

Table 103. Green Valley Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 104. Green Valley Recent Developments

Table 105. Vivoryon Corporation Information

Table 106. Vivoryon Description and Major Businesses

Table 107. Vivoryon Product Models, Descriptions and Specifications

Table 108. Vivoryon Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 109. Vivoryon Recent Developments

Table 110. Simcere Corporation Information

Table 111. Simcere Description and Major Businesses

Table 112. Simcere Product Models, Descriptions and Specifications

Table 113. Simcere Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 114. Simcere Recent Developments

Table 115. Johnson and Johnson Corporation Information

Table 116. Johnson and Johnson Description and Major Businesses

Table 117. Johnson and Johnson Product Models, Descriptions and Specifications

Table 118. Johnson and Johnson Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 119. Johnson and Johnson Recent Developments

Table 120. Key Raw Materials Distribution

Table 121. Raw Materials Key Suppliers

Table 122. Critical Raw Material Supplier Concentration (2024) & Risk Index

Table 123. Milestones in Production Technology Evolution

Table 124. Distributors List

Table 125. Market Trends and Market Evolution

Table 126. Market Drivers and Opportunities

Table 127. Market Challenges, Risks, and Restraints

Table 128. Research Programs/Design for This Report

Table 129. Key Data Information from Secondary Sources

Table 130. Key Data Information from Primary Sources

List of Figures

Figure 1. New Drug for Alzheimer's Treatment Product Picture

Figure 2. Global New Drug for Alzheimer's Treatment Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Figure 3. AChE Target Product Picture

Figure 4. Aβ Target Product Picture

Figure 5. BChE Target Product Picture

Figure 6. Others Product Picture

Figure 7. Global New Drug for Alzheimer's Treatment Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Figure 8. Preclinical Stage

Figure 9. Mild Cognitive Impairment Stage

Figure 10. Dementia Stage

Figure 11. New Drug for Alzheimer's Treatment Report Years Considered

Figure 12. Global New Drug for Alzheimer's Treatment Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 13. Global New Drug for Alzheimer's Treatment Revenue (2020-2031) & (US$ Million)

Figure 14. Global New Drug for Alzheimer's Treatment Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Figure 15. Global New Drug for Alzheimer's Treatment Revenue Market Share by Region (2020-2031)

Figure 16. Global New Drug for Alzheimer's Treatment Sales (2020-2031) & (K Dose)

Figure 17. Global New Drug for Alzheimer's Treatment Sales (CAGR) by Region (2020-2031) (K Dose)

Figure 18. Global New Drug for Alzheimer's Treatment Sales Market Share by Region (2020-2031)

Figure 19. Top 5 and Top 10 Manufacturers New Drug for Alzheimer's Treatment Sales Volume Market Share in 2024

Figure 20. Global New Drug for Alzheimer's Treatment Revenue Market Share Ranking (2024)

Figure 21. Tier Distribution by Revenue Contribution (2020 VS 2024)

Figure 22. AChE Target Revenue Market Share by Manufacturer in 2024

Figure 23. Aβ Target Revenue Market Share by Manufacturer in 2024

Figure 24. BChE Target Revenue Market Share by Manufacturer in 2024

Figure 25. Others Revenue Market Share by Manufacturer in 2024

Figure 26. Global New Drug for Alzheimer's Treatment Sales Market Share by Type (2020-2031)

Figure 27. Global New Drug for Alzheimer's Treatment Revenue Market Share by Type (2020-2031)

Figure 28. Global New Drug for Alzheimer's Treatment Sales Market Share by Application (2020-2031)

Figure 29. Global New Drug for Alzheimer's Treatment Revenue Market Share by Application (2020-2031)

Figure 30. North America New Drug for Alzheimer's Treatment Sales YoY (2020-2031) & (K Dose)

Figure 31. North America New Drug for Alzheimer's Treatment Revenue YoY (2020-2031) & (US$ Million)

Figure 32. North America Top 5 Manufacturers New Drug for Alzheimer's Treatment Sales Revenue (US$ Million) in 2024

Figure 33. North America New Drug for Alzheimer's Treatment Sales Volume (K Dose) by Type (2020- 2031)

Figure 34. North America New Drug for Alzheimer's Treatment Sales Revenue (US$ Million) by Type (2020 - 2031)

Figure 35. North America New Drug for Alzheimer's Treatment Sales Volume (K Dose) by Application (2020-2031)

Figure 36. North America New Drug for Alzheimer's Treatment Sales Revenue (US$ Million) by Application (2020-2031)

Figure 37. US New Drug for Alzheimer's Treatment Revenue (2020-2031) & (US$ Million)

Figure 38. Canada New Drug for Alzheimer's Treatment Revenue (2020-2031) & (US$ Million)

Figure 39. Mexico New Drug for Alzheimer's Treatment Revenue (2020-2031) & (US$ Million)

Figure 40. Europe New Drug for Alzheimer's Treatment Sales YoY (2020-2031) & (K Dose)

Figure 41. Europe New Drug for Alzheimer's Treatment Revenue YoY (2020-2031) & (US$ Million)

Figure 42. Europe Top 5 Manufacturers New Drug for Alzheimer's Treatment Sales Revenue (US$ Million) in 2024

Figure 43. Europe New Drug for Alzheimer's Treatment Sales Volume (K Dose) by Type (2020-2031)

Figure 44. Europe New Drug for Alzheimer's Treatment Sales Revenue (US$ Million) by Type (2020-2031)

Figure 45. Europe New Drug for Alzheimer's Treatment Sales Volume (K Dose) by Application (2020-2031)

Figure 46. Europe New Drug for Alzheimer's Treatment Sales Revenue (US$ Million) by Application (2020-2031)

Figure 47. Germany New Drug for Alzheimer's Treatment Revenue (2020-2031) & (US$ Million)

Figure 48. France New Drug for Alzheimer's Treatment Revenue (2020-2031) & (US$ Million)

Figure 49. U.K. New Drug for Alzheimer's Treatment Revenue (2020-2031) & (US$ Million)

Figure 50. Italy New Drug for Alzheimer's Treatment Revenue (2020-2031) & (US$ Million)

Figure 51. Russia New Drug for Alzheimer's Treatment Revenue (2020-2031) & (US$ Million)

Figure 52. Asia-Pacific New Drug for Alzheimer's Treatment Sales YoY (2020-2031) & (K Dose)

Figure 53. Asia-Pacific New Drug for Alzheimer's Treatment Revenue YoY (2020-2031) & (US$ Million)

Figure 54. Asia-Pacific Top 8 Manufacturers New Drug for Alzheimer's Treatment Sales Revenue (US$ Million) in 2024

Figure 55. Asia-Pacific New Drug for Alzheimer's Treatment Sales Volume (K Dose) by Type (2020- 2031)

Figure 56. Asia-Pacific New Drug for Alzheimer's Treatment Sales Revenue (US$ Million) by Type (2020- 2031)

Figure 57. Asia-Pacific New Drug for Alzheimer's Treatment Sales Volume (K Dose) by Application (2020-2031)

Figure 58. Asia-Pacific New Drug for Alzheimer's Treatment Sales Revenue (US$ Million) by Application (2020-2031)

Figure 59. Indonesia New Drug for Alzheimer's Treatment Revenue (2020-2031) & (US$ Million)

Figure 60. Japan New Drug for Alzheimer's Treatment Revenue (2020-2031) & (US$ Million)

Figure 61. South Korea New Drug for Alzheimer's Treatment Revenue (2020-2031) & (US$ Million)

Figure 62. China Taiwan New Drug for Alzheimer's Treatment Revenue (2020-2031) & (US$ Million)

Figure 63. India New Drug for Alzheimer's Treatment Revenue (2020-2031) & (US$ Million)

Figure 64. Central and South America New Drug for Alzheimer's Treatment Sales YoY (2020-2031) & (K Dose)

Figure 65. Central and South America New Drug for Alzheimer's Treatment Revenue YoY (2020-2031) & (US$ Million)

Figure 66. Central and South America Top 5 Manufacturers New Drug for Alzheimer's Treatment Sales Revenue (US$ Million) in 2024

Figure 67. Central and South America New Drug for Alzheimer's Treatment Sales Volume (K Dose) by Type (2021-2031)

Figure 68. Central and South America New Drug for Alzheimer's Treatment Sales Revenue (US$ Million) by Type (2020-2031)

Figure 69. Central and South America New Drug for Alzheimer's Treatment Sales Volume (K Dose) by Application (2020-2031)

Figure 70. Central and South America New Drug for Alzheimer's Treatment Sales Revenue (US$ Million) by Application (2020-2031)

Figure 71. Brazil New Drug for Alzheimer's Treatment Revenue (2020-2025) & (US$ Million)

Figure 72. Argentina New Drug for Alzheimer's Treatment Revenue (2020-2025) & (US$ Million)

Figure 73. Middle East, and Africa New Drug for Alzheimer's Treatment Sales YoY (2020-2031) & (K Dose)

Figure 74. Middle East and Africa New Drug for Alzheimer's Treatment Revenue YoY (2020-2031) & (US$ Million)

Figure 75. Middle East and Africa Top 5 Manufacturers New Drug for Alzheimer's Treatment Sales Revenue (US$ Million) in 2024

Figure 76. Middle East and Africa New Drug for Alzheimer's Treatment Sales Volume (K Dose) by Type (2021-2031)

Figure 77. South America New Drug for Alzheimer's Treatment Sales Revenue (US$ Million) by Type (2020-2031)

Figure 78. Middle East and Africa New Drug for Alzheimer's Treatment Sales Volume (K Dose) by Application (2020-2031)

Figure 79. Middle East and Africa New Drug for Alzheimer's Treatment Sales Revenue (US$ Million) by Application (2020-2031)

Figure 80. GCC Countries New Drug for Alzheimer's Treatment Revenue (2020-2025) & (US$ Million)

Figure 81. Turkey New Drug for Alzheimer's Treatment Revenue (2020-2025) & (US$ Million)

Figure 82. Egypt New Drug for Alzheimer's Treatment Revenue (2020-2025) & (US$ Million)

Figure 83. South Africa New Drug for Alzheimer's Treatment Revenue (2020-2025) & (US$ Million)

Figure 84. New Drug for Alzheimer's Treatment Industry Chain Mapping

Figure 85. Regional New Drug for Alzheimer's Treatment Manufacturing Base Distribution (%)

Figure 86. Global New Drug for Alzheimer's Treatment Production Market Share by Region (2020-2031)

Figure 87. New Drug for Alzheimer's Treatment Production Process

Figure 88. Regional New Drug for Alzheimer's Treatment Production Cost Structure

Figure 89. Channels of Distribution (Direct Vs Distribution)

Figure 90. Bottom-up and Top-down Approaches for This Report

Figure 91. Data Triangulation

Figure 92. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$4900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions